![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: FAM32A |
Gene summary for FAM32A |
![]() |
Gene information | Species | Human | Gene symbol | FAM32A | Gene ID | 26017 |
Gene name | family with sequence similarity 32 member A | |
Gene Alias | OTAG-12 | |
Cytomap | 19p13.11 | |
Gene Type | protein-coding | GO ID | GO:0006915 | UniProtAcc | A0A024R7I4 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
26017 | FAM32A | SYSMH6 | Human | Oral cavity | OSCC | 7.76e-09 | 4.01e-01 | 0.1275 |
26017 | FAM32A | P4_S8_cSCC | Human | Skin | cSCC | 5.68e-11 | 2.03e-01 | -0.3095 |
26017 | FAM32A | P5_S10_cSCC | Human | Skin | cSCC | 5.24e-03 | 1.10e-01 | -0.299 |
26017 | FAM32A | P1_cSCC | Human | Skin | cSCC | 1.54e-26 | 9.21e-01 | 0.0292 |
26017 | FAM32A | P2_cSCC | Human | Skin | cSCC | 3.28e-21 | 6.66e-01 | -0.024 |
26017 | FAM32A | P4_cSCC | Human | Skin | cSCC | 5.60e-17 | 6.59e-01 | -0.00290000000000005 |
26017 | FAM32A | P10_cSCC | Human | Skin | cSCC | 7.17e-14 | 6.94e-01 | 0.1017 |
26017 | FAM32A | cSCC_p8 | Human | Skin | cSCC | 1.15e-02 | 1.37e-01 | -0.1971 |
26017 | FAM32A | male-WTA | Human | Thyroid | PTC | 4.49e-39 | 2.07e-01 | 0.1037 |
26017 | FAM32A | PTC01 | Human | Thyroid | PTC | 1.43e-09 | 6.16e-02 | 0.1899 |
26017 | FAM32A | PTC03 | Human | Thyroid | PTC | 9.64e-05 | -3.81e-03 | 0.1784 |
26017 | FAM32A | PTC04 | Human | Thyroid | PTC | 1.20e-14 | -1.02e-02 | 0.1927 |
26017 | FAM32A | PTC05 | Human | Thyroid | PTC | 1.58e-10 | 3.03e-01 | 0.2065 |
26017 | FAM32A | PTC06 | Human | Thyroid | PTC | 2.55e-15 | 4.51e-01 | 0.2057 |
26017 | FAM32A | PTC07 | Human | Thyroid | PTC | 3.99e-32 | 4.25e-01 | 0.2044 |
26017 | FAM32A | ATC09 | Human | Thyroid | ATC | 2.06e-11 | 1.14e-01 | 0.2871 |
26017 | FAM32A | ATC12 | Human | Thyroid | ATC | 4.33e-06 | 2.45e-01 | 0.34 |
26017 | FAM32A | ATC13 | Human | Thyroid | ATC | 2.36e-33 | 7.78e-01 | 0.34 |
26017 | FAM32A | ATC1 | Human | Thyroid | ATC | 9.94e-09 | 1.78e-01 | 0.2878 |
26017 | FAM32A | ATC2 | Human | Thyroid | ATC | 1.20e-09 | 1.09e+00 | 0.34 |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FAM32A | SNV | Missense_Mutation | c.196N>C | p.Glu66Gln | p.E66Q | Q9Y421 | protein_coding | tolerated(0.32) | probably_damaging(0.987) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
FAM32A | SNV | Missense_Mutation | novel | c.271N>A | p.Asp91Asn | p.D91N | Q9Y421 | protein_coding | tolerated(0.09) | benign(0.041) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
FAM32A | SNV | Missense_Mutation | c.182N>T | p.Ala61Val | p.A61V | Q9Y421 | protein_coding | deleterious(0.01) | probably_damaging(0.984) | TCGA-A6-6653-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
FAM32A | SNV | Missense_Mutation | novel | c.38A>C | p.Lys13Thr | p.K13T | Q9Y421 | protein_coding | deleterious(0) | probably_damaging(0.961) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
FAM32A | SNV | Missense_Mutation | c.138G>T | p.Lys46Asn | p.K46N | Q9Y421 | protein_coding | tolerated(0.27) | probably_damaging(0.911) | TCGA-BS-A0UV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
FAM32A | SNV | Missense_Mutation | novel | c.121N>G | p.Met41Val | p.M41V | Q9Y421 | protein_coding | tolerated(0.48) | benign(0.028) | TCGA-WX-AA44-01 | Liver | liver hepatocellular carcinoma | Female | <65 | I/II | Targeted Molecular therapy | sorafenib | PR |
FAM32A | SNV | Missense_Mutation | c.332C>T | p.Thr111Met | p.T111M | Q9Y421 | protein_coding | deleterious(0.02) | benign(0.09) | TCGA-44-2657-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
FAM32A | SNV | Missense_Mutation | novel | c.305N>G | p.His102Arg | p.H102R | Q9Y421 | protein_coding | deleterious(0) | benign(0.029) | TCGA-VQ-A8E3-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
Page: 1 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |